Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients

Gloria Dalla Costa, Vittorio Martinelli, Lucia Moiola, Francesca Sangalli, Bruno Colombo, Annamaria Finardi, Paola Cinque, Eva Maria Kolb, Aiden Haghikia, Ralf Gold, Roberto Furlan, Giancarlo Comi

Research output: Contribution to journalArticlepeer-review

Abstract

This study analyzed serum neurofilament light chains (NfL) in 2 European cohorts of 312 multiple sclerosis (MS) patients to investigate whether NfL are biomarkers of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment. The cohort comprised 25 PML, 136 natalizumab-treated, and 151 untreated MS patients. Patients subsequently developing PML had similar NfL to other natalizumab-treated MS patients. At PML onset, NfL were 10-fold higher than in the pre-PML condition and in natalizumab-treated or untreated MS patients, and NfL continued to increase until onset of immune reconstitution inflammatory syndrome. The results suggest that in natalizumab-treated patients, NfL may represent an early and accessible marker of PML. Ann Neurol 2019;85:606–610.

Original languageEnglish
Pages (from-to)606-610
Number of pages5
JournalAnnals of Neurology
Volume85
Issue number4
DOIs
Publication statusPublished - Apr 2019

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients'. Together they form a unique fingerprint.

Cite this